Skip to main
PVLA

PVLA Stock Forecast & Price Target

PVLA Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Palvella Therapeutics is a clinical-stage biopharmaceutical company with a positive outlook, driven by its management team's operating leverage and positive data from clinical trials for its lead product candidate, QTORIN rapamycin. The company's broad pipeline, particularly in using rapamycin to target the mTOR pathway, provides significant potential for scalability and platform characteristics that could attract strategic interest. However, there are risks, including the need for significant additional funding and potential challenges to patents from competitors. The company's expansion of QTORIN into potential treatments for other indications could further enhance its market potential.

Bears say

Palvella Therapeutics is facing significant risks in its clinical development due to the length and cost of trials, as well as the uncertainty of success. There are concerns about the company's lead candidate, QTORIN, which relies on an unproven technology and has shown mixed results in clinical trials. Additionally, there is competition in the market, with other treatments potentially hindering standard-of-care adoption. The company also faces risks in financing and may need to raise additional capital before reaching profitability.

PVLA has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Palvella Therapeutics Inc (PVLA) Forecast

Analysts have given PVLA a Strong Buy based on their latest research and market trends.

According to 14 analysts, PVLA has a Strong Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $190.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $190.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Palvella Therapeutics Inc (PVLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.